EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 1 / Phase 2	2025-09-25		NCT06448572

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Exeliom Biosciences	2
University Hospital, Lille	194

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
CHU Lille	Lille	France	22

Clinical trials